32 patients with Eaton-Glickel stage 2-3 CMC arthritis will be randomized to receive intraarticular MFAT or intraarticular corticosteroid injection. Patients with inflammatory arthritis or prior thumb base trauma or surgery will be excluded. Autologous adipose tissue will be harvested from the outer thigh or lower abdomen using local anesthesia. Tissue will be processed to remove oil and debris in-office using an FDA-approved commercially available device. The processed adipose will be immediately injected into the thumb CMC joint under fluoroscopic guidance. Visual analogue score (VAS), grip/pinch strength, Kapandji range of motion score, thumb disability examination, and QuickDASH score will be assessed pre-procedure and at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.
No linked publications found in PubMed
Inclusion Criteria: 1. 18 years old or older; male and female patients 2. Eaton-Glickel stage 2-3 thumb CMC arthritis 3. Failed conservative treatment (i.e. hand therapy, pain medications, splinting) 4. Able to provide informed consent Exclusion Criteria: 1. Pregnancy/breastfeeding 2. Inflammatory or posttraumatic arthritis 3. Prior thumb base trauma or surgery 4. Evidence of skin infection or soft tissue loss at the thumb CMC joint or adipose harvest site 5. Active local or systemic malignancy 6. Known allergy to any study drug